Devang Bhuva

Devang Bhuva is a senior executive in the pharmaceutical industry, currently serving as the Senior Vice President of Corporate Development at Gilead Sciences.1 Based in the San Francisco Bay Area, Bhuva plays a crucial role in Gilead's strategic growth and expansion efforts.

Professional Background

Devang Bhuva has extensive experience in the biotechnology and pharmaceutical sectors. At Gilead Sciences, he is involved in key corporate development activities, including mergers and acquisitions, strategic partnerships, and pipeline expansion.

Recent Corporate Activities

Bhuva has been actively involved in several significant transactions for Gilead Sciences:

1. CymaBay Acquisition: In March 2024, Bhuva announced the completion of Gilead's acquisition of CymaBay, a move aimed at bringing a potential best-in-disease therapy to patients with Primary Biliary Cholangitis (PBC).2

2. Dragonfly Collaboration: In May 2022, he shared news about Gilead's strategic research collaboration with Dragonfly Therapeutics to develop Natural Killer Cell Engagers in Oncology and Inflammation.3

3. XinThera Acquisition: Bhuva reported on Gilead's acquisition of XinThera in May 2023, which was intended to strengthen the company's early pipeline in oncology and inflammation.4

These activities demonstrate Bhuva's involvement in Gilead's efforts to expand its therapeutic portfolio and enhance its position in key disease areas.

Professional Network

Devang Bhuva maintains a strong professional presence on LinkedIn, with over 500 connections.1 His profile serves as a platform for sharing important company updates and industry insights, particularly in the areas of biotechnology and pharmaceutical development.